Battle Over Mandated Part D Rebates Gets Tougher: AARP Endorses House Bill
This article was originally published in The Pink Sheet Daily
Executive Summary
Influential lobbying group plans national advertising and extensive grassroots outreach to directly support the House's version of health care reform legislation over the more pharma-friendly Senate Finance Committee bill.
You may also be interested in...
Merged House Bill Seeks More Part D Savings, Broader Medicaid Expansion
The health care reform bill unveiled by the House leadership Oct. 29 seeks increased drug savings for the Medicare Part D program through mandated rebates for products provided to low-income beneficiaries and by requiring HHS to negotiate drug pricing directly with manufacturers
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.